Encepheal Therapeutics YC 지원서

Summer 2019Inactive

Encepheal Therapeutics은(는) Summer 2019 배치에서 Healthcare 회사로 Y Combinator를 거쳤습니다. 아래에는 회사의 사업 내용, 창립자, 그리고 실제 YC 양식에 맞춰 재구성한 YC 지원서가 있습니다.

YC 배치: Summer 2019
산업: HealthcareTherapeutics
팀 규모: 3
상태: Inactive
출시됨: 2019

창업자

Aaron LazarusFounder
Omeed RahimiFounder

Encepheal Therapeutics의 사업 내용

EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments. Our small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examples of this for opioid use disorder. However, these types of medications can be addictive themselves. This has been a major hurdle for medication development for cocaine addiction and has led to many leaders in the addiction space to abandon the dopamine transporter as a target. At EncepHeal, we believe that the dopamine transporter should not be abandoned and instead focusing on fixing the abuse liability problem. Therefore with our partners at the National Institutes of Health, we have shown that these new, allosteric modulators at the dopamine transporter do not display addictive tendencies in animal models. They are also effective at curbing cocaine addiction. Our management team has two co-founders, Omeed Rahimi and Aaron Lazarus, as well as an experienced addiction pharmacologist as their research officer. The team has an advisory board with entrepreneurial and addiction drug development experience as well as expert partners at the National Institute on Drug Abuse, a subset of the NIH, and Wake Forest. Our team has had success in raising non-dilutive funding and has expertise with SBIR/STTR grants. We are looking for help in better connecting with the biotech/pharmaceutical industry.

Encepheal Therapeutics의 YC 지원서, 재구성됨

Y Combinator 지원

Encepheal Therapeutics, Summer 2019 기수. 공개 데이터를 기반으로 작성된 실제 지원 질문.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Encepheal Therapeutics

Describe what your company does in 50 characters or less.

Medications to treat substance abuse

What is your company going to make? Please describe your product and what it does or will do.

We're developing small molecule drugs that target the dopamine transporter to treat stimulant addiction, starting with cocaine and methamphetamine. Our compounds modulate the dopamine transporter allosterically to reduce addictive cravings without the addictive properties of current dopamine transporter inhibitors.

Where do you live now, and where would the company be based after YC?

We currently live and work in Winston-Salem, NC, and the company is based there. After YC, we plan to maintain our base in Winston-Salem due to our partnerships and existing infrastructure.

Explain your decision regarding location.

We chose Winston-Salem because we have strong research collaborations with the National Institutes of Health and Wake Forest, which are local. This proximity helps us advance our drug development efficiently.

전체 지원서에서 21개의 추가 답변

Founders, Progress, Idea, Equity, Curious, Batch Preference는 전체 버전에 있습니다. 무료 계정을 만들어 YC Insights에서 모든 YC 배치 옆에 열어보세요.

전체 지원 보기

자주 묻는 질문

Encepheal Therapeutics의 실제 YC 지원서인가요?

아닙니다. Y Combinator는 제출된 지원서를 비공개로 유지합니다. 이것은 재구성된 것입니다. 실제 YC 양식 질문에 Encepheal Therapeutics의 공개 데이터(출시 노트, 창업자 배경, 제품 설명)를 기반으로 답변했습니다. Encepheal Therapeutics과 같은 회사가 YC에 어떻게 자신을 소개하는지 보여주며, 그들이 제출한 텍스트는 아닙니다.